Patents by Inventor Dhanya Raveendra Panickar

Dhanya Raveendra Panickar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF
    Publication number: 20230113588
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 13, 2023
    Inventors: Nicholas David Peter COSFORD, Dhanya RAVEENDRA-PANICKAR, Douglas J. SHEFFLER, John Howard HUTCHINSON, Reto Andreas GADIENT
  • Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
    Patent number: 11447453
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: September 20, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient
  • METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF
    Publication number: 20200347021
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: March 12, 2020
    Publication date: November 5, 2020
    Inventors: Nicholas David Peter COSFORD, Dhanya RAVEENDRA-PANICKAR, Douglas J. SHEFFLER, John Howard HUTCHINSON, Reto Andreas GADIENT
  • ULK1 inhibitors and methods using same
    Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • ULK1 inhibitors and methods using same
    Patent number: 10689397
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 23, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
    Patent number: 10597367
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: March 24, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190284207
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: April 19, 2019
    Publication date: September 19, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190248806
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 15, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20190152989
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Inventors: Reuben J. SHAW, Daniel F. EGAN, Nicholas COSFORD, Benjamin TURK, Mitchell VAMOS, Dhanya Raveendra PANICKAR, Matthew CHUN, Douglas SHEFFLER
  • ULK1 inhibitors and methods using same
    Patent number: 10266549
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 23, 2019
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF
    Publication number: 20190016715
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: April 11, 2018
    Publication date: January 17, 2019
    Inventors: Nicholas David Peter COSFORD, Dhanya RAVEENDRA-PANICKAR, Douglas J. SHEFFLER
  • Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
    Patent number: 9969726
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: May 15, 2018
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler
  • NOVEL ULK1 INHIBITORS AND METHODS USING SAME
    Publication number: 20170342088
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: August 25, 2015
    Publication date: November 30, 2017
    Applicants: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, YALE UNIVERSITY
    Inventors: REUBEN J. SHAW, DANIEL F. EGAN, NICHOLAS COSFORD, BENJAMIN TURK, MITCHELL VAMOS, DHANYA RAVEENDRA PANICKAR, MATTHEW CHUN, DOUG SHEFFLER
  • Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof
    Publication number: 20170217951
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: June 9, 2015
    Publication date: August 3, 2017
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Nicholas David Peter COSFORD, DHANYA Raveendra-Panickar, Douglas J. SHEFFLER
  • Positive allosteric modulators of group II mGluRs
    Patent number: 8748632
    Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2) receptor, and for treating CNS disorders associated with the mGlu2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 10, 2014
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Nicholas D. P. Cosford, Dhanya Raveendra Panickar, Shyama Sidique, Svetlana Semenova, Athinia Markou
  • POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS
    Publication number: 20120071503
    Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2) receptor, and for treating CNS disorders associated with the mGlu2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.
    Type: Application
    Filed: March 18, 2011
    Publication date: March 22, 2012
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Nicholas D. P. Cosford, Dhanya Raveendra Panickar, Shyama Sidique